Prosecution Insights
Last updated: August 18, 2026

Examiner: STEELE, AMBER D

Tech Center 1600 • Art Units: 1627 1639 1645 1654 1658 1676

This examiner grants 59% of resolved cases

Performance Statistics

59.0%
Allow Rate
-1.0% vs TC avg
879
Total Applications
+9.7%
Interview Lift
1252
Avg Prosecution Days
Based on 818 resolved cases, 2023–2026

Rejection Statute Breakdown

8.1%
§101 Eligibility
20.2%
§102 Novelty
25.7%
§103 Obviousness
25.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17768537 Bi-Peptide with Affinity to Extracellular Matrix Proteins or Cells and to Growth Factors for Tissue Healing and Regeneration Final Rejection Mayo Foundation for Medical Education and Research
17433009 CARBAMOYL PHOSPHATE SYNTHATASE-1 FOR THE TREATMENT AND PREVENTION OF LIVER INJURY Non-Final OA The Regents of the University of Michigan
19351688 PROCESSES AND INTERMEDIATES FOR PREPARING TIRZEPATIDE Final Rejection ELI LILLY AND COMPANY
17760668 Conformationally-Constrained Alpha-RGIA Analogues Non-Final OA University of Utah Research Foundation
18037098 VIBRIO TOXIN BINDING PROTEINS IN SHRIMP AND USES THEREOF Final Rejection ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
18872790 PREVENTING ALU SINES-MEDIATED PATHOLOGIES Non-Final OA UNIVERSITY OF SOUTH FLORIDA
17296795 PEPTIDE LIGANDS FOR CAPTURE OF HOST CELL PROTEINS Final Rejection North Carolina State University
18564739 Substrate-specific adhesive peptides Non-Final OA HENKEL AG & CO. KGAA
18265883 METHODS OF MAKING WATER-SOLUBLE PROTEIN FORMED IN A BACTERIAL EXPRESSION SYSTEM, COMPOSITIONS, AND METHODS OF USE THEREOF Final Rejection THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
18580971 COMPOSITION FOR PREVENTING OR TREATING LIVER DISEASES, COMPRISING STC-1 OR DERIVATIVE THEREOF Non-Final OA INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
17169835 SEPARATION OF VWF AND VWF PROPEPTIDE BY CHROMATOGRAPHIC METHODS Final Rejection Takeda Pharmaceutical Company Limited
17396304 Growth Hormone-Releasing Hormone Antagonists and Uses Thereof Final Rejection University of Miami
18426877 Treatment of Homologous Recombination Deficient Cancers Final Rejection Sinai Health System
18530002 MODIFIED SERPINS FOR THE TREATMENT OF BRADYKININ-MEDIATED DISEASE Non-Final OA PRECLINICS GESELLSCHAFT FÜR PRÄKLINISCHE FORSCHUNG MBH
18273336 INTRANASAL FORMULATIONS AND DELIVERY OF SOMATOSTATIN MIMETICS AND USES THEREOF Non-Final OA NBO PHARMA INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month